Human	B-OG
β	B-GP
-	I-GP
Defensin	I-GP
3	I-GP
Reduces	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
Induced	O
Inflammation	O
and	O
Monocyte	O
Adhesion	O
in	O
Human	B-OG
Umbilical	O
Vein	O
Endothelial	O
Cells	O

Academic	O
Editor	O
:	O
Ulrich	O
Eisel	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
human	B-OG
β	B-GP
-	I-GP
defensin	I-GP
3	I-GP
(	O
hBD3	B-GP
)	O
in	O
the	O
initiation	O
stage	O
of	O
atherosclerosis	B-DS
with	O
human	B-OG
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
triggered	O
by	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
-	O
(	B-GP
TNF	I-GP
-)	I-GP
α	I-GP
.	O

The	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
injury	O
and	O
inflammatory	O
response	O
were	O
evaluated	O
.	O

Our	O
data	O
revealed	O
that	O
first	O
,	O
hBD3	B-GP
reduced	O
the	O
production	O
of	O
interleukin	B-GP
-	I-GP
6	I-GP
(	O
IL	B-GP
-	I-GP
6	I-GP
),	O
IL	B-GP
-	I-GP
8	I-GP
,	O
monocyte	B-GP
chemoattractant	I-GP
protein	I-GP
-	I-GP
1	I-GP
(	O
MCP	B-GP
-	I-GP
1	I-GP
),	O
and	O
macrophage	B-GP
migration	I-GP
inhibitory	I-GP
factor	I-GP
(	O
MIF	B-GP
)	O
in	O
HUVECs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
hBD3	B-GP
significantly	O
prevented	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
by	O
HUVECs	O
.	O

Second	O
,	O
western	O
blot	O
analysis	O
demonstrated	O
that	O
hBD3	B-GP
dose	O
-	O
dependently	O
suppressed	O
the	O
protein	O
levels	O
of	O
intracellular	B-GP
adhesion	I-GP
molecule	I-GP
-	I-GP
1	I-GP
(	O
ICAM	B-GP
-	I-GP
1	I-GP
)	O
and	O
vascular	B-GP
cell	I-GP
adhesion	I-GP
molecule	I-GP
-	I-GP
1	I-GP
(	O
VCAM	B-GP
-	I-GP
1	I-GP
)	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
HUVECs	O
.	O

As	O
a	O
result	O
,	O
hBD3	B-GP
inhibited	O
monocyte	O
adhesion	O
to	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
treated	O
endothelial	O
cells	O
.	O

Additionally	O
,	O
hBD3	B-GP
suppressed	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
F	B-GP
-	I-GP
actin	I-GP
reorganization	O
in	O
HUVECs	O
.	O

Third	O
,	O
hBD3	B-GP
markedly	O
inhibited	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
by	O
decreasing	O
the	O
phosphorylation	O
of	O
IKK	B-GP
-	I-GP
α	I-GP
/	O
β	O
,	O
IκB	B-GP
,	O
and	O
p65	B-GP
subunit	O
within	O
30	O
min	O
.	O

Moreover	O
,	O
the	O
phosphorylation	O
of	O
p38	B-GP
and	O
c	B-GP
-	I-GP
Jun	I-GP
N	I-GP
-	I-GP
terminal	I-GP
protein	I-GP
kinase	I-GP
(	O
JNK	B-GP
)	O
in	O
the	O
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
(	O
MAPK	B-GP
)	O
pathway	O
were	O
also	O
inhibited	O
by	O
hBD3	B-GP
in	O
HUVECs	O
.	O

In	O
conclusion	O
,	O
hBD3	B-GP
exerts	O
anti	O
-	O
inflammatory	O
and	O
antioxidative	O
effects	O
in	O
endothelial	O
cells	O
in	O
response	O
to	O
TNF	B-GP
-	I-GP
α	I-GP
by	O
inhibiting	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
signaling	O
.	O

1	O
.	O

Introduction	O

Atherosclerosis	B-DS
is	O
a	O
vascular	B-DS
inflammatory	I-DS
disease	I-DS
characterized	O
by	O
the	O
accumulation	O
of	O
lipids	O
and	O
immune	O
cells	O
on	O
the	O
inner	O
face	O
of	O
the	O
arterial	O
wall	O
.	O

Inflammatory	O
stimulation	O
,	O
even	O
low	O
level	O
endotoxemia	B-DS
,	O
can	O
aggravate	O
the	O
progression	O
of	O
this	O
disease	O
[	O
1	O
].	O

A	O
monolayer	O
of	O
endothelial	O
cells	O
,	O
which	O
directly	O
contacts	O
the	O
flowing	O
blood	O
,	O
is	O
easily	O
attacked	O
by	O
various	O
stimulating	O
factors	O
.	O

Endothelial	O
cell	O
dysfunction	O
triggered	O
by	O
such	O
stimulations	O
is	O
believed	O
to	O
be	O
the	O
initiation	O
step	O
and	O
key	O
contributor	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DS
[	O
2	O
].	O

Endothelial	O
cells	O
at	O
sites	O
of	O
inflammation	O
are	O
not	O
only	O
participants	O
but	O
also	O
regulators	O
of	O
inflammation	O
[	O
3	O
,	O
4	O
].	O

During	O
inflammation	O
,	O
a	O
large	O
amount	O
of	O
inflammatory	O
mediators	O
are	O
produced	O
by	O
immune	O
cells	O
,	O
such	O
as	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
are	O
the	O
main	O
targets	O
.	O

Then	O
,	O
the	O
activated	O
endothelial	O
cells	O
secrete	O
a	O
broad	O
spectrum	O
of	O
cytokines	B-GP
and	O
chemokines	B-GP
,	O
recruiting	O
monocytes	O
.	O

Enhanced	O
migration	O
and	O
adhesion	O
of	O
monocytes	O
to	O
the	O
endothelium	O
are	O
suggested	O
to	O
play	O
a	O
crucial	O
role	O
in	O
atherosclerosis	B-DS
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
required	O
for	O
the	O
firm	O
binding	O
of	O
monocytes	O
is	O
also	O
upregulated	O
on	O
endothelial	O
cell	O
surfaces	O
[	O
5	O
].	O

In	O
our	O
previous	O
study	O
,	O
the	O
results	O
demonstrated	O
that	O
chronic	O
exposure	O
to	O
the	O
endotoxin	O
of	O
Porphyromonas	B-OG
gingivalis	I-OG
can	O
aggravate	O
atherosclerotic	B-DS
lesions	I-DS
in	O
ApoE	B-GP
-	O
deficient	O
mice	B-OG
[	O
6	O
].	O

Indeed	O
,	O
compelling	O
evidence	O
has	O
demonstrated	O
the	O
proatherogenic	O
role	O
of	O
inflammatory	B-GP
cytokines	I-GP
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DS
.	O

Elevated	O
levels	O
of	O
several	O
inflammatory	O
markers	O
in	O
the	O
circulation	O
are	O
risk	O
factors	O
for	O
atherosclerotic	O
events	O
[	O
7	O
].	O

Tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
α	I-GP
(	O
TNF	B-GP
-	I-GP
α	I-GP
),	O
one	O
of	O
the	O
most	O
potent	O
inflammatory	B-GP
cytokines	I-GP
,	O
is	O
closely	O
associated	O
with	O
atherosclerosis	B-DS
.	O

It	O
is	O
mainly	O
produced	O
by	O
activated	O
macrophages	O
.	O

It	O
is	O
a	O
pleiotropic	O
cytokine	B-GP
mediating	O
inflammation	O
,	O
immunity	O
,	O
and	O
apoptosis	O
.	O

For	O
vascular	O
endothelial	O
cells	O
,	O
exposure	O
to	O
TNF	B-GP
-	I-GP
α	I-GP
triggers	O
several	O
signaling	O
cascades	O
in	O
human	B-OG
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
),	O
especially	O
the	O
nuclear	B-GP
factor	I-GP
κB	I-GP
(	O
NF	B-GP
-	I-GP
κB	I-GP
),	O
c	B-GP
-	I-GP
Jun	I-GP
N	I-GP
-	I-GP
terminal	I-GP
kinase	I-GP
(	O
JNK	B-GP
),	O
and	O
p38	B-GP
mitogen	I-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
pathways	O
,	O
leading	O
to	O
the	O
production	O
of	O
inflammatory	B-GP
cytokines	I-GP
[	O
8	O
].	O

In	O
addition	O
,	O
TNF	B-GP
-	I-GP
α	I-GP
can	O
reorganize	O
the	O
F	B-GP
-	I-GP
actin	I-GP
cytoskeleton	O
of	O
endothelial	O
cells	O
,	O
leading	O
to	O
the	O
formation	O
of	O
stress	O
fibers	O
[	O
9	O
].	O

TNF	B-GP
-	I-GP
α	I-GP
can	O
also	O
modulate	O
EC	O
permeability	O
by	O
enlarging	O
intercellular	O
gaps	O
,	O
promoting	O
vascular	O
leakage	O
at	O
sites	O
of	O
inflammation	O
[	O
10	O
].	O

TNF	B-GP
-	I-GP
α	I-GP
stimulation	O
is	O
also	O
associated	O
with	O
increased	O
intracellular	O
levels	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
formation	O
,	O
enhancing	O
monocyte	O
recruitment	O
and	O
adhesion	O
to	O
the	O
vascular	O
endothelium	O
.	O

This	O
process	O
is	O
mediated	O
mainly	O
by	O
elevated	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
such	O
as	O
intercellular	B-GP
adhesion	I-GP
molecule	I-GP
-	I-GP
1	I-GP
(	O
ICAM	B-GP
-	I-GP
1	I-GP
),	O
vascular	B-GP
cell	I-GP
adhesion	I-GP
molecule	I-GP
-	I-GP
1	I-GP
(	O
VCAM	B-GP
-	I-GP
1	I-GP
),	O
and	O
endothelial	B-GP
cell	I-GP
selectin	I-GP
(	O
E	B-GP
-	I-GP
selectin	I-GP
).	O

Defensins	B-GP
are	O
naturally	O
occurring	O
peptides	O
with	O
a	O
wide	O
range	O
of	O
antimicrobial	O
,	O
antiviral	O
,	O
and	O
immunomodulatory	O
properties	O
.	O

They	O
are	O
cationic	O
,	O
cysteine	O
-	O
rich	O
,	O
β	O
-	O
sheet	O
,	O
and	O
tridisulfide	O
peptides	O
.	O

In	O
humans	B-OG
,	O
defensins	B-GP
are	O
classified	O
into	O
two	O
categories	O
,	O
α	O
-	O
and	O
β	B-GP
-	I-GP
defensins	I-GP
.	O
β	B-GP
-	I-GP
defensins	I-GP
are	O
mainly	O
produced	O
by	O
the	O
mucosa	O
and	O
epithelial	O
cells	O
.	O

Intraocular	O
tissues	O
and	O
the	O
human	B-OG
endometrium	O
are	O
also	O
reported	O
to	O
express	O
β	B-GP
-	I-GP
defensins	I-GP
[	O
11	O
].	O

Several	O
studies	O
have	O
documented	O
the	O
participation	O
of	O
antimicrobial	B-GP
peptides	I-GP
in	O
endothelial	O
immune	O
defense	O
[	O
12	O
,	O
13	O
].	O

In	O
addition	O
,	O
β	B-GP
-	I-GP
defensins	I-GP
are	O
beneficial	O
for	O
wound	O
healing	O
of	O
endothelial	O
cells	O
[	O
14	O
].	O

Human	B-OG
β	B-GP
-	I-GP
defensin	I-GP
3	I-GP
(	O
hBD3	B-GP
)	O
is	O
a	O
member	O
of	O
the	O
β	B-GP
-	I-GP
defensin	I-GP
family	O
.	O

In	O
addition	O
to	O
epithelial	O
cells	O
,	O
hBD3	B-GP
is	O
also	O
expressed	O
in	O
endothelial	O
cells	O
.	O

The	O
gene	O
and	O
protein	O
expression	O
of	O
hBD3	B-GP
are	O
induced	O
in	O
human	B-OG
umbilical	O
vein	O
endothelial	O
cells	O
simulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
[	O
15	O
].	O

The	O
upregulation	O
of	O
hBD3	B-GP
by	O
TNF	B-GP
-	I-GP
α	I-GP
in	O
HUVECs	O
illustrates	O
the	O
important	O
role	O
that	O
defensins	B-GP
play	O
in	O
host	O
immune	O
defense	O
against	O
inflammation	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
hBD3	B-GP
strongly	O
inhibited	O
the	O
progression	O
of	O
early	O
-	O
stage	O
atherosclerotic	B-DS
lesions	I-DS
and	O
inflammation	O
levels	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
and	O
human	B-OG
THP	O
-	O
1	O
-	O
derived	O
macrophages	O
[	O
16	O
,	O
17	O
].	O

However	O
,	O
the	O
cell	O
types	O
targeted	O
by	O
hBD3	B-GP
might	O
not	O
be	O
restricted	O
to	O
macrophages	O
.	O

Vascular	O
endothelial	O
cells	O
and	O
monocytes	O
/	O
macrophages	O
are	O
both	O
atherogenic	O
and	O
critical	O
components	O
in	O
the	O
process	O
of	O
atherogenesis	O
[	O
18	O
].	O

The	O
interaction	O
between	O
macrophages	O
and	O
endothelial	O
cells	O
is	O
very	O
crucial	O
in	O
atherosclerosis	B-DS
.	O

In	O
normal	O
conditions	O
,	O
resting	O
endothelial	O
cells	O
form	O
an	O
integrated	O
barrier	O
at	O
the	O
blood	O
-	O
tissue	O
interface	O
.	O

Upon	O
inflammatory	O
stimulation	O
,	O
quiescent	O
endothelial	O
cells	O
may	O
transform	O
into	O
a	O
proatherogenic	O
phenotype	O
,	O
inducing	O
the	O
infiltration	O
of	O
monocytes	O
[	O
19	O
].	O

The	O
recruited	O
monocytes	O
then	O
differentiate	O
into	O
macrophages	O
,	O
contributing	O
to	O
a	O
vicious	O
cycle	O
promoting	O
endothelial	B-DS
dysfunction	I-DS
[	O
20	O
].	O

As	O
the	O
endothelium	O
has	O
already	O
been	O
a	O
therapeutic	O
target	O
,	O
hBD3	B-GP
might	O
also	O
manifest	O
its	O
protective	O
effects	O
by	O
interacting	O
with	O
vessel	O
endothelial	O
cells	O
.	O

The	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
cell	O
activation	O
remain	O
unknown	O
.	O

Thus	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
focus	O
on	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
endothelial	O
cell	O
dysfunction	O
,	O
including	O
the	O
enhanced	O
production	O
of	O
inflammatory	O
mediators	O
,	O
monocyte	O
adhesion	O
,	O
and	O
the	O
expression	O
of	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
,	O
all	O
of	O
which	O
are	O
early	O
events	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DS
.	O

2	O
.	O

Materials	O
and	O
Methods	O

2	O
.	O
1	O
.	O

Cell	O
Culture	O
and	O
Reagents	O

Human	B-OG
primary	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
(	O
ScienCell	O
Research	O
Laboratories	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
were	O
maintained	O
in	O
endothelial	O
cell	O
medium	O
(	O
ECM	O
)	O
(	O
ScienCell	O
Research	O
Laboratories	O
)	O
supplemented	O
with	O
5	O
%	O
FBS	O
,	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
,	O
and	O
1	O
%	O
endothelial	O
cell	O
growth	O
supplement	O
(	O
ECGS	O
).	O

For	O
the	O
present	O
study	O
,	O
cells	O
at	O
passages	O
3	O
–	O
6	O
were	O
seeded	O
and	O
grown	O
until	O
confluence	O
.	O

Recombinant	O
human	B-OG
TNF	B-GP
-	I-GP
α	I-GP
and	O
hBD3	B-GP
were	O
obtained	O
from	O
PeproTech	O
(	O
Rocky	O
Hill	O
,	O
NJ	O
,	O
USA	O
).	O

Anti	O
-	O
ICAM	B-GP
-	I-GP
1	I-GP
and	O
anti	O
-	O
VCAM	B-GP
-	I-GP
1	I-GP
antibodies	B-GP
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
).	O

Antiphosphorylated	O
and	O
total	O
IκBα	B-GP
,	O
p65	B-GP
,	O
p38	B-GP
,	O
ERK	B-GP
,	O
and	O
JNK	B-GP
antibodies	B-GP
were	O
purchased	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Beverly	O
,	O
MA	O
).	O

2	O
.	O
2	O
.	O

Cell	O
Viability	O
Assay	O

The	O
cell	O
viability	O
of	O
HUVECs	O
was	O
determined	O
using	O
a	O
CCK8	O
assay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

HUVECs	O
(	O
5000	O
cells	O
/	O
well	O
)	O
were	O
prepared	O
in	O
96	O
-	O
well	O
plates	O
and	O
incubated	O
overnight	O
before	O
treatment	O
with	O
various	O
concentrations	O
of	O
hBD3	B-GP
(	O
20	O
,	O
10	O
,	O
5	O
,	O
2	O
.	O
5	O
,	O
or	O
1	O
.	O
25	O
μg	O
/	O
mL	O
)	O
and	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O

Subsequently	O
,	O
10	O
μL	O
of	O
CCK8	O
solution	O
(	O
Dojindo	O
Laboratories	O
,	O
Kumamoto	O
,	O
Japan	O
)	O
was	O
added	O
to	O
each	O
well	O
,	O
and	O
the	O
cells	O
were	O
incubated	O
for	O
an	O
additional	O
3	O
h	O
.	O

The	O
optical	O
density	O
of	O
each	O
well	O
was	O
evaluated	O
at	O
a	O
wavelength	O
of	O
450	O
nm	O
on	O
a	O
microplate	O
spectrophotometer	O
.	O

2	O
.	O
3	O
.	O

Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
)	O

HUVECs	O
were	O
seeded	O
and	O
cultured	O
in	O
a	O
96	O
-	O
well	O
plate	O
until	O
confluent	O
.	O

The	O
control	O
group	O
was	O
treated	O
with	O
ECM	O
and	O
the	O
other	O
seven	O
groups	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
hBD3	B-GP
for	O
24	O
h	O
.	O

Then	O
the	O
cell	O
supernatants	O
were	O
collected	O
by	O
centrifugation	O
.	O

The	O
assay	O
was	O
performed	O
with	O
specific	O
ELISA	O
kits	O
(	O
R	O
&	O
D	O
Systems	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

2	O
.	O
4	O
.	O

Monocyte	O
Adhesion	O
Assay	O

Confluent	O
HUVECs	O
were	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
hBD3	B-GP
for	O
24	O
h	O
.	O

After	O
that	O
,	O
the	O
cells	O
were	O
washed	O
with	O
RPMI	O
-	O
1640	O
medium	O
before	O
being	O
cocultured	O
with	O
THP	O
-	O
1	O
cells	O
.	O

THP	O
-	O
1	O
cells	O
were	O
prelabeled	O
with	O
2	O
μM	O
calcein	O
-	O
AM	O
(	O
Dojindo	O
Laboratories	O
)	O
in	O
RPMI	O
-	O
1640	O
medium	O
for	O
20	O
min	O
in	O
the	O
cell	O
incubator	O
before	O
being	O
added	O
to	O
each	O
well	O
of	O
HUVECs	O
and	O
further	O
incubated	O
for	O
30	O
min	O
.	O

After	O
coincubation	O
,	O
each	O
well	O
was	O
washed	O
gently	O
and	O
thoroughly	O
with	O
RPMI	O
-	O
1640	O
medium	O
supplemented	O
with	O
1	O
%	O
FBS	O
to	O
remove	O
the	O
nonadherent	O
THP	O
-	O
1	O
cells	O
.	O

The	O
attached	O
THP	O
-	O
1	O
cells	O
were	O
examined	O
under	O
a	O
microscope	O
(	O
Olympus	O
Corporation	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
fluorescence	O
microplate	O
reader	O
at	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
490	O
nm	O
and	O
515	O
nm	O
.	O

2	O
.	O
5	O
.	O

Western	O
Blot	O
Analysis	O

The	O
cells	O
were	O
lysed	O
in	O
RIPA	O
buffer	O
supplemented	O
with	O
protease	B-GP
inhibitors	O
for	O
30	O
min	O
,	O
and	O
the	O
whole	O
cell	O
lysates	O
were	O
separated	O
by	O
electrophoresis	O
in	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gels	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
then	O
transferred	O
to	O
PVDF	O
membranes	O
(	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
).	O

The	O
membranes	O
were	O
blocked	O
with	O
5	O
%	O
BSA	B-GP
at	O
room	O
temperature	O
for	O
2	O
h	O
before	O
incubation	O
overnight	O
with	O
primary	O
antibodies	B-GP
against	O
the	O
target	O
protein	O
.	O

Blots	O
were	O
washed	O
with	O
Tris	O
-	O
buffered	O
saline	O
containing	O
0	O
.	O
1	O
%	O
Tween	O
20	O
three	O
times	O
and	O
then	O
incubated	O
for	O
2	O
h	O
with	O
anti	O
-	O
rabbit	B-OG
secondary	O
antibody	B-GP
at	O
room	O
temperature	O
.	O

The	O
bands	O
were	O
detected	O
using	O
chemiluminescence	O
detection	O
agents	O
.	O

Images	O
were	O
captured	O
with	O
an	O
ImageQuant	O
LAS	O
4000	O
digital	O
imaging	O
system	O
(	O
GE	O
Healthcare	O
,	O
Piscataway	O
,	O
NJ	O
).	O

2	O
.	O
6	O
.	O

Immunofluorescence	O
Analysis	O

HUVECs	O
were	O
seeded	O
onto	O
sterile	O
glass	O
coverslips	O
in	O
a	O
12	O
-	O
well	O
cell	O
culture	O
plate	O
.	O

After	O
incubation	O
overnight	O
,	O
the	O
cells	O
were	O
treated	O
with	O
the	O
indicated	O
concentrations	O
of	O
hBD3	B-GP
under	O
TNF	B-GP
-	I-GP
α	I-GP
stimulation	O
for	O
the	O
indicated	O
time	O
.	O

Subsequently	O
,	O
the	O
cells	O
were	O
washed	O
and	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
for	O
20	O
min	O
at	O
room	O
temperature	O
and	O
then	O
treated	O
with	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
for	O
15	O
min	O
.	O

After	O
that	O
,	O
the	O
cells	O
were	O
blocked	O
with	O
3	O
%	O
BSA	B-GP
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
the	O
cells	O
were	O
further	O
incubated	O
with	O
the	O
indicated	O
rabbit	B-OG
primary	O
antibody	B-GP
at	O
4	O
°	O
C	O
overnight	O
,	O
followed	O
by	O
incubation	O
with	O
a	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
secondary	O
antibody	B-GP
conjugated	O
to	O
Alexa	O
Fluor	O
488	O
(	O
for	O
NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
)	O
(	O
1	O
:	O
1000	O
,	O
Abcam	O
)	O
or	O
Alexa	O
Fluor	O
594	O
(	O
for	O
ICAM	B-GP
-	I-GP
1	I-GP
)	O
(	O
1	O
:	O
1000	O
,	O
Abcam	O
)	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

The	O
slides	O
were	O
then	O
mounted	O
with	O
one	O
drop	O
of	O
mounting	O
medium	O
that	O
contained	O
DAPI	O
.	O

NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
and	O
ICAM	B-GP
-	I-GP
1	I-GP
were	O
imaged	O
using	O
a	O
confocal	O
microscope	O
.	O

ICAM	B-GP
-	I-GP
1	I-GP
was	O
visualized	O
as	O
red	O
and	O
NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
was	O
visualized	O
as	O
green	O
,	O
with	O
nuclei	O
as	O
blue	O
.	O

2	O
.	O
7	O
.	O

Measurement	O
of	O
Intracellular	O
Reactive	O
Oxygen	O
Species	O

Intracellular	O
ROS	O
formation	O
was	O
determined	O
with	O
DCFH	O
-	O
DA	O
(	O
KeyGEN	O
,	O
Jiangsu	O
,	O
China	O
).	O

HUVECs	O
were	O
seeded	O
in	O
black	O
96	O
-	O
well	O
plates	O
.	O

Subsequently	O
,	O
the	O
cells	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
with	O
or	O
without	O
indicated	O
concentrations	O
of	O
hBD3	B-GP
for	O
2	O
h	O
.	O

The	O
cells	O
were	O
then	O
washed	O
with	O
PBS	O
and	O
incubated	O
with	O
20	O
μM	O
DCFH	O
-	O
DA	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
in	O
the	O
dark	O
.	O

The	O
fluorescence	O
level	O
was	O
determined	O
using	O
a	O
fluorescence	O
microplate	O
reader	O
at	O
an	O
excitation	O
wavelength	O
of	O
485	O
nm	O
and	O
an	O
emission	O
wavelength	O
of	O
530	O
nm	O
.	O

2	O
.	O
8	O
.	O

F	B-GP
-	I-GP
Actin	I-GP
Staining	O

Human	B-OG
umbilical	O
vein	O
endothelial	O
cells	O
were	O
cultured	O
and	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
as	O
indicated	O
.	O

Then	O
,	O
the	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
at	O
room	O
temperature	O
for	O
20	O
min	O
.	O

After	O
that	O
,	O
the	O
actin	B-GP
cytoskeleton	O
was	O
stained	O
with	O
DyLight	O
488	O
-	O
phalloidin	O
,	O
and	O
the	O
nuclei	O
were	O
stained	O
with	O
DAPI	O
.	O

Stained	O
HUVECs	O
were	O
visualized	O
using	O
a	O
confocal	O
microscope	O
(	O
Olympus	O
FV	O
10i	O
).	O

2	O
.	O
9	O
.	O

Statistical	O
Analysis	O

Data	O
are	O
expressed	O
as	O
the	O
means	O
±	O
SD	O
.	O

Comparison	O
between	O
different	O
treatments	O
was	O
performed	O
using	O
GraphPad	O
PRISM	O
software	O
version	O
6	O
.	O
0	O
using	O
one	O
-	O
way	O
ANOVA	O
with	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
.	O

Statistical	O
significance	O
was	O
set	O
at	O
p	O
values	O
<	O
0	O
.	O
05	O
.	O

3	O
.	O

Results	O

3	O
.	O
1	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
the	O
Viability	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
Induced	O
Endothelial	O
Cells	O

Numerous	O
studies	O
have	O
demonstrated	O
that	O
TNF	B-GP
-	I-GP
α	I-GP
treatment	O
can	O
impair	O
endothelial	O
cell	O
viability	O
and	O
induce	O
apoptosis	O
.	O

First	O
,	O
we	O
evaluated	O
the	O
cytotoxic	O
effects	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
on	O
HUVECs	O
using	O
a	O
CCK8	O
assay	O
.	O

All	O
data	O
are	O
expressed	O
as	O
the	O
survival	O
percentage	O
of	O
each	O
group	O
relative	O
to	O
the	O
control	O
group	O
,	O
which	O
is	O
defined	O
as	O
100	O
%.	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
TNF	B-GP
-	I-GP
α	I-GP
at	O
a	O
concentration	O
of	O
40	O
ng	O
/	O
mL	O
could	O
markedly	O
suppress	O
the	O
proliferation	O
of	O
HUVECs	O
by	O
nearly	O
50	O
%.	O

In	O
addition	O
,	O
treatment	O
with	O
hBD3	B-GP
at	O
5	O
μg	O
/	O
mL	O
and	O
10	O
μg	O
/	O
mL	O
markedly	O
recovered	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
impaired	O
cell	O
viability	O
to	O
about	O
79	O
.	O
1	O
%	O
and	O
101	O
.	O
7	O
%,	O
respectively	O
.	O

The	O
results	O
also	O
suggested	O
that	O
hBD3	B-GP
does	O
not	O
influence	O
the	O
viability	O
of	O
HUVECs	O
.	O

3	O
.	O
2	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
the	O
Production	O
of	O
Proinflammatory	O
Mediators	O
by	O
Endothelial	O
Cells	O
Stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
endothelial	O
cell	O
activation	O
stimulated	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

Endothelial	O
cells	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
produce	O
proinflammatory	O
mediators	O
,	O
including	O
interleukin	B-GP
-	I-GP
(	I-GP
IL	I-GP
-)	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
and	O
monocyte	B-GP
chemoattractant	I-GP
protein	I-GP
-	I-GP
1	I-GP
(	O
MCP	B-GP
-	I-GP
1	I-GP
),	O
which	O
cause	O
more	O
monocytes	O
to	O
be	O
recruited	O
.	O

These	O
proinflammatory	O
mediators	O
are	O
reported	O
to	O
aggravate	O
endothelial	B-DS
dysfunction	I-DS
.	O

As	O
shown	O
in	O
Figure	O
2	O
(	O
a	O
),	O
when	O
the	O
cells	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
for	O
24	O
h	O
,	O
IL	B-GP
-	I-GP
8	I-GP
production	O
in	O
the	O
supernatant	O
was	O
significantly	O
elevated	O
;	O
however	O
,	O
with	O
hBD3	B-GP
intervention	O
,	O
IL	B-GP
-	I-GP
8	I-GP
level	O
was	O
markedly	O
and	O
dose	O
-	O
dependently	O
inhibited	O
.	O

The	O
same	O
trend	O
of	O
IL	B-GP
-	I-GP
6	I-GP
and	O
MCP	B-GP
-	I-GP
1	I-GP
was	O
also	O
observed	O
in	O
Figures	O
2	O
(	O
b	O
)	O
and	O
2	O
(	O
c	O
).	O

Macrophage	B-GP
migration	I-GP
inhibitory	I-GP
factor	I-GP
(	O
MIF	B-GP
)	O
is	O
a	O
key	O
factor	O
mediating	O
the	O
interactions	O
between	O
macrophages	O
and	O
endothelial	O
cells	O
[	O
21	O
].	O

It	O
is	O
considered	O
to	O
interact	O
with	O
other	O
proinflammatory	B-GP
cytokines	I-GP
during	O
inflammation	O
.	O

There	O
is	O
evidence	O
showing	O
it	O
is	O
a	O
potent	O
activator	O
of	O
macrophages	O
released	O
by	O
activated	O
endothelial	O
cells	O
.	O

The	O
release	O
of	O
MIF	B-GP
by	O
HUVECs	O
was	O
markedly	O
inhibited	O
in	O
response	O
to	O
hBD3	B-GP
treatment	O
(	O
Figure	O
2	O
(	O
d	O
)).	O

3	O
.	O
3	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
the	O
Expression	O
of	O
Adhesion	B-GP
Molecules	I-GP
by	O
HUVECs	O

Accumulated	O
evidence	O
supports	O
a	O
role	O
for	O
adhesion	B-GP
molecules	I-GP
in	O
the	O
progression	O
of	O
atherosclerosis	B-DS
.	O

ICAM	B-GP
-	I-GP
1	I-GP
and	O
VCAM	B-GP
-	I-GP
1	I-GP
are	O
constitutively	O
expressed	O
on	O
the	O
surface	O
of	O
HUVECs	O
,	O
and	O
E	B-GP
-	I-GP
selectin	I-GP
is	O
only	O
expressed	O
on	O
the	O
activated	O
endothelium	O
[	O
22	O
].	O

The	O
interaction	O
of	O
E	B-GP
-	I-GP
selectin	I-GP
and	O
leukocytes	O
mediates	O
the	O
rolling	O
of	O
leukocytes	O
on	O
the	O
activated	O
endothelium	O
,	O
which	O
is	O
the	O
first	O
event	O
in	O
firm	O
adhesion	O
.	O

TNF	B-GP
-	I-GP
α	I-GP
is	O
known	O
to	O
transiently	O
upregulate	O
the	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
,	O
such	O
as	O
ICAM	B-GP
-	I-GP
1	I-GP
and	O
VCAM	B-GP
-	I-GP
1	I-GP
,	O
in	O
HUVECs	O
[	O
23	O
].	O

We	O
then	O
evaluated	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
the	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
induced	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

As	O
demonstrated	O
in	O
Figure	O
3	O
(	O
a	O
),	O
treatment	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
significantly	O
enhanced	O
the	O
expression	O
level	O
of	O
ICAM	B-GP
-	I-GP
1	I-GP
(	O
24	O
h	O
),	O
VCAM	B-GP
-	I-GP
1	I-GP
(	O
24	O
h	O
),	O
and	O
E	B-GP
-	I-GP
selectin	I-GP
(	O
4	O
h	O
).	O

In	O
addition	O
,	O
hBD3	B-GP
treatment	O
dose	O
-	O
dependently	O
prevented	O
the	O
upregulation	O
of	O
ICAM	B-GP
-	I-GP
1	I-GP
,	O
VCAM	B-GP
-	I-GP
1	I-GP
,	O
and	O
E	B-GP
-	I-GP
selectin	I-GP
levels	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

The	O
immunofluorescence	O
staining	O
assay	O
also	O
validated	O
the	O
inhibitory	O
effects	O
of	O
hBD3	B-GP
(	O
15	O
μg	O
/	O
mL	O
)	O
on	O
ICAM	B-GP
-	I-GP
1	I-GP
expression	O
levels	O
triggered	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
Figure	O
3	O
(	O
b	O
)).	O

3	O
.	O
4	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
Monocyte	O
Adhesion	O
to	O
Endothelial	O
Cells	O

During	O
the	O
initiation	O
of	O
atherosclerosis	B-DS
,	O
endothelial	O
cells	O
are	O
activated	O
and	O
upregulate	O
adhesion	B-GP
molecules	I-GP
and	O
chemokine	B-GP
and	O
cytokine	B-GP
secretion	O
,	O
which	O
is	O
beneficial	O
for	O
monocyte	O
recruitment	O
.	O

Due	O
to	O
the	O
significant	O
decrease	O
in	O
cell	O
surface	O
adhesion	B-GP
molecules	I-GP
and	O
proinflammatory	O
mediators	O
in	O
hBD3	B-GP
-	O
treated	O
HUVECs	O
,	O
we	O
investigated	O
whether	O
hBD3	B-GP
could	O
affect	O
the	O
attachment	O
of	O
immune	O
cells	O
to	O
endothelial	O
cells	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
THP	O
-	O
1	O
monocyte	O
adhesion	O
to	O
HUVECs	O
in	O
a	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
proinflammatory	O
environment	O
,	O
HUVECs	O
were	O
seeded	O
and	O
cultured	O
to	O
about	O
90	O
%	O
confluence	O
and	O
then	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
hBD3	B-GP
(	O
15	O
μg	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O

Subsequently	O
,	O
HUVECs	O
were	O
cocultured	O
with	O
prelabeled	O
THP	O
-	O
1	O
cells	O
for	O
30	O
min	O
.	O

After	O
removal	O
of	O
nonadherent	O
THP	O
-	O
1	O
cells	O
by	O
gentle	O
washing	O
,	O
images	O
were	O
captured	O
under	O
a	O
fluorescence	O
microscope	O
.	O

As	O
shown	O
in	O
Figures	O
4	O
(	O
a	O
)	O
and	O
4	O
(	O
b	O
),	O
we	O
observed	O
that	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
TNF	B-GP
-	I-GP
α	I-GP
treatment	O
resulted	O
in	O
a	O
4	O
-	O
fold	O
increase	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
THP	O
-	O
1	O
attachment	O
to	O
HUVECs	O
.	O

However	O
,	O
hBD3	B-GP
intervention	O
significantly	O
decreased	O
THP	O
-	O
1	O
adhesion	O
to	O
HUVECs	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

3	O
.	O
5	O
.	O

hBD3	B-GP
Suppressed	O
Activation	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
Pathways	O
in	O
HUVECs	O

NF	B-GP
-	I-GP
κB	I-GP
is	O
considered	O
as	O
an	O
important	O
regulator	O
of	O
the	O
proinflammatory	O
process	O
and	O
monocyte	O
adhesion	O
.	O

To	O
identify	O
the	O
probable	O
molecular	O
mechanism	O
responsible	O
for	O
hBD3	B-GP
involvement	O
in	O
the	O
modulation	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
treated	O
HUVECs	O
,	O
we	O
first	O
evaluated	O
the	O
classical	O
NF	B-GP
-	I-GP
κB	I-GP
signaling	O
pathway	O
.	O

Here	O
,	O
we	O
show	O
that	O
hBD3	B-GP
strongly	O
inhibits	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
HUVECs	O
via	O
two	O
distinct	O
signaling	O
pathways	O
,	O
an	O
NF	B-GP
-	I-GP
κB	I-GP
-	O
dependent	O
pathway	O
and	O
the	O
MAPK	B-GP
pathway	O
.	O

We	O
examined	O
key	O
factors	O
in	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
with	O
western	O
blot	O
.	O

Activation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
required	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IκB	B-GP
.	O

As	O
shown	O
in	O
Figure	O
5	O
(	O
a	O
),	O
degradation	O
and	O
phosphorylation	O
of	O
IκB	B-GP
were	O
significantly	O
suppressed	O
by	O
the	O
addition	O
of	O
hBD3	B-GP
.	O

The	O
effective	O
role	O
of	O
hBD3	B-GP
to	O
prevent	O
phosphorylation	O
of	O
p65	B-GP
subunit	O
was	O
also	O
observed	O
.	O

In	O
addition	O
,	O
phosphorylated	O
IKKα	B-GP
,	O
which	O
is	O
the	O
upstream	O
modulator	O
in	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
,	O
was	O
also	O
inhibited	O
by	O
hBD3	B-GP
.	O

To	O
validate	O
this	O
result	O
,	O
immunofluorescence	O
staining	O
was	O
used	O
to	O
determine	O
NF	B-GP
-	I-GP
κB	I-GP
nuclear	O
translocation	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
(	O
b	O
),	O
NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
was	O
predominantly	O
located	O
within	O
the	O
cytoplasm	O
in	O
unstimulated	O
cells	O
.	O

With	O
TNF	B-GP
-	I-GP
α	I-GP
treatment	O
,	O
p65	B-GP
translocated	O
to	O
the	O
nucleus	O
within	O
30	O
min	O
.	O

However	O
,	O
treatment	O
with	O
hBD3	B-GP
at	O
15	O
μg	O
/	O
mL	O
led	O
to	O
retention	O
of	O
the	O
p65	B-GP
subunit	O
in	O
the	O
cytoplasm	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
cells	O
.	O

We	O
then	O
investigated	O
the	O
role	O
of	O
the	O
MAPK	B-GP
pathway	O
in	O
this	O
process	O
.	O

The	O
key	O
components	O
of	O
the	O
MAPK	B-GP
pathway	O
,	O
p38	B-GP
,	O
ERK	B-GP
,	O
and	O
JNK	B-GP
were	O
evaluated	O
with	O
a	O
western	O
blot	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
(	O
c	O
),	O
treatment	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
resulted	O
in	O
a	O
significant	O
increase	O
of	O
phosphorylation	O
in	O
the	O
MAPK	B-GP
pathway	O
.	O

The	O
phosphorylation	O
of	O
p38	B-GP
and	O
JNK	B-GP
was	O
significantly	O
and	O
concentration	O
-	O
dependently	O
suppressed	O
by	O
hBD3	B-GP
at	O
30	O
min	O
,	O
while	O
the	O
phosphorylation	O
of	O
ERK	B-GP
was	O
not	O
altered	O
.	O

The	O
cell	O
lysates	O
obtained	O
at	O
45	O
min	O
also	O
validated	O
this	O
result	O
.	O

3	O
.	O
6	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
the	O
Activation	O
of	O
Caspases	B-GP
and	O
Bcl	B-GP
-	I-GP
2	I-GP
Expression	O
in	O
HUVECs	O

TNF	B-GP
-	I-GP
α	I-GP
has	O
been	O
reported	O
to	O
stimulate	O
apoptosis	O
in	O
HUVECs	O
.	O

In	O
addition	O
,	O
the	O
cleavage	O
of	O
caspase	B-GP
-	I-GP
3	I-GP
is	O
a	O
key	O
step	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
cell	O
death	O
.	O

Before	O
activation	O
,	O
caspase	B-GP
-	I-GP
3	I-GP
exists	O
as	O
an	O
inactive	O
form	O
.	O

After	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
treatment	O
,	O
caspase	B-GP
-	I-GP
3	I-GP
was	O
cleaved	O
to	O
the	O
active	O
form	O
.	O

The	O
activation	O
of	O
caspases	B-GP
is	O
considered	O
one	O
mechanism	O
of	O
apoptosis	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
the	O
activation	O
of	O
caspases	B-GP
.	O

HUVECs	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
for	O
6	O
h	O
.	O

The	O
expression	O
levels	O
of	O
caspase	B-GP
-	I-GP
3	I-GP
were	O
examined	O
with	O
western	O
blot	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
expression	O
levels	O
of	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
significantly	O
increased	O
following	O
TNF	B-GP
-	I-GP
α	I-GP
treatment	O
,	O
while	O
hBD3	B-GP
markedly	O
suppressed	O
this	O
phenomenon	O
.	O

Meanwhile	O
,	O
we	O
examined	O
the	O
expression	O
level	O
of	O
Bcl	B-GP
-	I-GP
2	I-GP
.	O

As	O
shown	O
in	O
Figure	O
6	O
,	O
there	O
was	O
a	O
clear	O
decrease	O
in	O
the	O
expression	O
of	O
Bcl	B-GP
-	I-GP
2	I-GP
after	O
treatment	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

These	O
results	O
suggested	O
that	O
hBD3	B-GP
inhibited	O
the	O
apoptosis	O
of	O
HUVECs	O
stimulated	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

3	O
.	O
7	O
.	O

hBD3	B-GP
Suppressed	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
Induced	O
ROS	O
Formation	O
in	O
HUVECs	O

It	O
has	O
been	O
suggested	O
that	O
the	O
enhanced	O
production	O
of	O
intracellular	O
ROS	O
can	O
lead	O
to	O
cell	O
apoptosis	O
.	O

To	O
measure	O
the	O
potential	O
modulation	O
of	O
apoptosis	O
and	O
oxidative	O
stress	O
by	O
hBD3	B-GP
,	O
the	O
production	O
of	O
ROS	O
was	O
evaluated	O
for	O
fluorescence	O
intensity	O
in	O
HUVECs	O
.	O

As	O
revealed	O
in	O
Figure	O
7	O
(	O
a	O
),	O
HUVECs	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
produced	O
an	O
intracellular	O
burst	O
of	O
ROS	O
(	O
about	O
3	O
.	O
9	O
-	O
fold	O
change	O
).	O

The	O
intracellular	O
ROS	O
production	O
in	O
HUVECs	O
was	O
significantly	O
suppressed	O
when	O
treated	O
with	O
hBD3	B-GP
.	O

However	O
,	O
the	O
basal	O
level	O
of	O
ROS	O
was	O
not	O
altered	O
by	O
treatment	O
with	O
hBD3	B-GP
alone	O
.	O

3	O
.	O
8	O
.	O

hBD3	B-GP
Repressed	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
Induced	O
F	B-GP
-	I-GP
Actin	I-GP
Reorganization	O
in	O
HUVECs	O

TNF	B-GP
-	I-GP
α	I-GP
is	O
reported	O
to	O
have	O
the	O
ability	O
to	O
alter	O
the	O
permeability	O
and	O
morphology	O
of	O
endothelial	O
cells	O
.	O

To	O
investigate	O
the	O
role	O
of	O
hBD3	B-GP
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
function	O
,	O
HUVECs	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
hBD3	B-GP
(	O
15	O
μg	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O

Then	O
,	O
the	O
cells	O
were	O
fixed	O
and	O
stained	O
with	O
phalloidin	O
.	O

As	O
shown	O
in	O
Figure	O
8	O
,	O
stimulating	O
HUVECs	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
formation	O
of	O
actin	B-GP
stress	O
fibers	O
.	O

In	O
addition	O
,	O
hBD3	B-GP
treatment	O
markedly	O
reduced	O
this	O
alteration	O
in	O
HUVECs	O
.	O

4	O
.	O

Discussion	O

Atherosclerosis	B-DS
is	O
defined	O
as	O
a	O
chronic	O
inflammatory	O
-	O
fibroproliferative	O
response	O
of	O
the	O
vascular	O
wall	O
to	O
various	O
forms	O
of	O
inflammatory	O
stimuli	O
.	O

Disruption	O
of	O
the	O
endothelial	O
cell	O
barrier	O
induced	O
by	O
proinflammatory	B-GP
cytokines	I-GP
,	O
such	O
as	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
is	O
the	O
initiating	O
step	O
of	O
this	O
disease	O
.	O

Endothelial	O
cells	O
maintain	O
vascular	O
homeostasis	O
via	O
the	O
secretion	O
of	O
several	O
vasoactive	O
factors	O
,	O
and	O
impairment	O
of	O
barrier	O
integrity	O
leads	O
to	O
the	O
development	O
of	O
vascular	B-DS
inflammatory	I-DS
diseases	I-DS
,	O
such	O
as	O
atherosclerosis	B-DS
.	O

As	O
a	O
monolayer	O
in	O
direct	O
contact	O
with	O
the	O
bloodstream	O
,	O
the	O
vascular	O
endothelium	O
is	O
the	O
principal	O
physiological	O
target	O
of	O
the	O
proinflammatory	O
actions	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IL	B-GP
-	I-GP
1	I-GP
.	O

Extensive	O
evidence	O
has	O
suggested	O
that	O
the	O
endothelium	O
is	O
not	O
simply	O
the	O
inner	O
cellular	O
lining	O
of	O
blood	O
vessels	O
[	O
24	O
].	O

Beyond	O
being	O
passively	O
targeted	O
,	O
endothelial	O
cells	O
are	O
believed	O
to	O
be	O
profoundly	O
involved	O
in	O
this	O
inflammatory	O
process	O
,	O
especially	O
in	O
the	O
regulation	O
of	O
effector	O
cells	O
,	O
such	O
as	O
monocytes	O
and	O
lymphocytes	O
.	O

Therefore	O
,	O
the	O
endothelium	O
may	O
act	O
as	O
a	O
therapeutic	O
target	O
due	O
to	O
its	O
critical	O
role	O
in	O
the	O
inflammatory	O
process	O
[	O
25	O
].	O

Macrophage	B-GP
migration	I-GP
inhibitory	I-GP
factor	I-GP
(	O
MIF	B-GP
)	O
is	O
one	O
of	O
the	O
most	O
important	O
cytokines	B-GP
produced	O
by	O
endothelial	O
cells	O
to	O
control	O
the	O
accumulation	O
of	O
effector	O
cells	O
[	O
26	O
].	O

It	O
is	O
recognized	O
as	O
an	O
effective	O
activator	O
of	O
macrophages	O
,	O
participating	O
in	O
the	O
process	O
of	O
recruitment	O
and	O
the	O
accumulation	O
of	O
macrophages	O
at	O
local	O
inflammatory	O
sites	O
.	O

As	O
monocyte	O
adhesion	O
to	O
the	O
endothelium	O
is	O
a	O
crucial	O
step	O
in	O
the	O
early	O
stages	O
of	O
atherosclerosis	B-DS
,	O
MIF	B-GP
is	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DS
and	O
is	O
closely	O
related	O
to	O
plaque	O
stability	O
[	O
27	O
].	O

Elevated	O
MIF	B-GP
expression	O
was	O
observed	O
in	O
response	O
to	O
some	O
immunostimulants	O
in	O
HUVECs	O
[	O
28	O
].	O

In	O
our	O
experiment	O
,	O
the	O
production	O
of	O
MIF	B-GP
was	O
markedly	O
increased	O
under	O
TNF	B-GP
-	I-GP
α	I-GP
stimulation	O
in	O
HUVECs	O
,	O
while	O
treatment	O
with	O
hBD3	B-GP
dose	O
-	O
dependently	O
reduced	O
MIF	B-GP
expression	O
.	O

This	O
result	O
was	O
also	O
confirmed	O
by	O
the	O
effect	O
of	O
hBD3	B-GP
in	O
inhibiting	O
the	O
adhesion	O
of	O
monocytes	O
to	O
endothelial	O
cells	O
.	O

A	O
prominent	O
feature	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
cell	O
injury	O
is	O
the	O
excess	O
generation	O
of	O
intracellular	O
ROS	O
.	O

Moderate	O
levels	O
of	O
ROS	O
have	O
been	O
reported	O
to	O
participate	O
in	O
the	O
physiological	O
functions	O
of	O
cells	O
,	O
while	O
the	O
overproduction	O
of	O
intracellular	O
ROS	O
is	O
closely	O
associated	O
with	O
the	O
progression	O
of	O
atherosclerosis	B-DS
[	O
29	O
,	O
30	O
].	O

Oxidative	O
stress	O
activates	O
endothelial	O
cells	O
,	O
causing	O
cell	O
injury	O
,	O
apoptosis	O
,	O
and	O
enhanced	O
monocyte	O
adhesion	O
.	O

In	O
the	O
present	O
study	O
,	O
treatment	O
with	O
hBD3	B-GP
attenuated	O
ROS	O
production	O
in	O
HUVECs	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

The	O
binding	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
to	O
cell	B-GP
surface	I-GP
receptors	I-GP
triggers	O
multiple	O
signaling	O
events	O
,	O
including	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
pathway	O
.	O

NF	B-GP
-	I-GP
κB	I-GP
has	O
been	O
demonstrated	O
to	O
be	O
a	O
key	O
transcription	B-GP
factor	I-GP
in	O
this	O
signaling	O
pathway	O
.	O

Activation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
is	O
closely	O
associated	O
with	O
the	O
initiation	O
and	O
progression	O
of	O
atherosclerosis	B-DS
.	O

In	O
resting	O
cells	O
,	O
NF	B-GP
-	I-GP
κB	I-GP
is	O
maintained	O
in	O
an	O
inactive	O
form	O
within	O
the	O
cytoplasm	O
by	O
the	O
inhibitor	B-GP
of	I-GP
κB	I-GP
(	O
IκB	B-GP
)	O
family	O
but	O
enters	O
the	O
nucleus	O
in	O
response	O
to	O
external	O
stimuli	O
,	O
such	O
as	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

IκB	B-GP
kinase	I-GP
-	O
(	O
IKK	B-GP
-)	O
dependent	O
phosphorylation	O
and	O
the	O
subsequent	O
ubiquitination	O
and	O
degradation	O
of	O
IκB	B-GP
make	O
NF	B-GP
-	I-GP
κB	I-GP
free	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
induce	O
downstream	O
transcription	O
[	O
31	O
].	O

NF	B-GP
-	I-GP
κB	I-GP
has	O
been	O
identified	O
as	O
an	O
important	O
target	O
in	O
the	O
treatment	O
of	O
atherosclerosis	B-DS
.	O

Our	O
data	O
revealed	O
that	O
hBD3	B-GP
markedly	O
reduced	O
the	O
phosphorylation	O
of	O
IκB	B-GP
.	O

Additionally	O
,	O
the	O
p65	B-GP
subunit	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
is	O
constitutively	O
phosphorylated	O
at	O
a	O
low	O
level	O
in	O
unstimulated	O
conditions	O
,	O
and	O
treatment	O
with	O
inflammatory	O
triggers	O
,	O
LPS	O
and	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
for	O
example	O
,	O
results	O
in	O
further	O
phosphorylation	O
.	O

The	O
total	O
level	O
of	O
phosphorylation	O
of	O
p65	B-GP
was	O
also	O
suppressed	O
by	O
the	O
addition	O
of	O
hBD3	B-GP
.	O

We	O
also	O
investigated	O
the	O
phosphorylation	O
of	O
IKK	B-GP
-	I-GP
α	I-GP
/	O
β	O
,	O
which	O
is	O
an	O
upstream	O
signaling	O
molecule	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
.	O

The	O
results	O
demonstrated	O
that	O
hBD3	B-GP
inhibited	O
IKK	B-GP
-	I-GP
α	I-GP
/	O
β	O
phosphorylation	O
30	O
min	O
after	O
TNF	B-GP
-	I-GP
α	I-GP
stimulation	O
.	O

In	O
addition	O
,	O
the	O
inhibition	O
of	O
ROS	O
generation	O
also	O
contributes	O
to	O
the	O
decrease	O
in	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
,	O
as	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
by	O
ROS	O
through	O
the	O
IKK	B-GP
pathway	O
has	O
been	O
suggested	O
[	O
32	O
].	O

The	O
downregulation	O
of	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
in	O
HUVECs	O
by	O
hBD3	B-GP
might	O
be	O
mediated	O
through	O
inhibition	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
,	O
as	O
the	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
mediated	O
increase	O
in	O
ICAM	B-GP
-	I-GP
1	I-GP
and	O
VCAM	B-GP
-	I-GP
1	I-GP
expression	O
is	O
mediated	O
through	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
,	O
not	O
the	O
MAPK	B-GP
pathway	O
[	O
33	O
].	O

Ample	O
evidence	O
has	O
documented	O
intensive	O
crosstalk	O
between	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
signaling	O
pathways	O
.	O

The	O
MAPK	B-GP
pathway	O
is	O
required	O
for	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
mediated	O
inflammation	O
[	O
34	O
].	O

In	O
addition	O
,	O
the	O
JNK	B-GP
pathway	O
was	O
suggested	O
to	O
promote	O
cell	O
apoptosis	O
[	O
35	O
].	O

hBD3	B-GP
was	O
reported	O
to	O
rapidly	O
enter	O
the	O
cells	O
and	O
impact	O
TLR	B-GP
signaling	O
pathway	O
associated	O
with	O
MyD88	B-GP
and	O
TRIF	B-GP
[	O
36	O
].	O

In	O
this	O
case	O
,	O
there	O
is	O
also	O
possibility	O
that	O
hBD3	B-GP
inhibits	O
TNF	B-GP
signaling	O
via	O
interaction	O
with	O
the	O
upstream	O
molecules	O
in	O
the	O
signaling	O
pathway	O
.	O

Further	O
research	O
needs	O
to	O
be	O
done	O
to	O
elucidate	O
this	O
problem	O
.	O

Human	B-OG
β	B-GP
-	I-GP
defensin	I-GP
3	I-GP
is	O
a	O
multifunctional	O
effector	O
molecule	O
involved	O
in	O
a	O
startling	O
range	O
of	O
cellular	O
processes	O
.	O

First	O
,	O
as	O
an	O
antimicrobial	O
peptide	O
,	O
hBD3	B-GP
exhibits	O
broad	O
antimicrobial	O
activity	O
against	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	B-OG
,	O
fungi	B-OG
,	O
and	O
viruses	B-OG
[	O
37	O
].	O

Second	O
,	O
it	O
was	O
demonstrated	O
to	O
have	O
immunomodulatory	O
effects	O
due	O
to	O
its	O
biphasic	O
effect	O
in	O
the	O
host	O
immune	O
response	O
.	O

It	O
can	O
be	O
either	O
proinflammatory	O
or	O
anti	O
-	O
inflammatory	O
,	O
depending	O
on	O
the	O
circumstances	O
[	O
38	O
,	O
39	O
].	O

In	O
addition	O
,	O
the	O
beneficial	O
effects	O
of	O
hBD3	B-GP
on	O
wound	O
healing	O
were	O
also	O
reported	O
[	O
40	O
].	O

We	O
previously	O
demonstrated	O
that	O
hBD3	B-GP
significantly	O
inhibited	O
the	O
progression	O
of	O
early	O
-	O
stage	O
atherosclerotic	B-DS
lesions	I-DS
,	O
and	O
this	O
effect	O
was	O
correlated	O
with	O
downregulation	O
of	O
macrophage	O
inflammation	O
.	O

To	O
date	O
,	O
there	O
is	O
no	O
study	O
focusing	O
on	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
inflammation	O
.	O

In	O
the	O
present	O
study	O
,	O
our	O
data	O
extend	O
the	O
protective	O
effects	O
of	O
hBD3	B-GP
to	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
cell	O
injury	O
.	O

Owing	O
to	O
their	O
strong	O
antimicrobial	O
activity	O
,	O
low	O
molecular	O
weight	O
,	O
and	O
immunogenicity	O
,	O
several	O
researchers	O
and	O
studies	O
are	O
focusing	O
on	O
the	O
clinical	O
use	O
of	O
antimicrobial	B-GP
peptides	I-GP
as	O
a	O
new	O
class	O
of	O
antibiotics	O
[	O
41	O
],	O
and	O
some	O
of	O
them	O
are	O
already	O
in	O
the	O
clinical	O
development	O
stage	O
[	O
42	O
].	O

However	O
,	O
β	B-GP
-	I-GP
defensins	I-GP
had	O
limited	O
success	O
in	O
clinical	O
application	O
.	O

The	O
reasons	O
include	O
the	O
high	O
synthesis	O
cost	O
and	O
short	O
half	O
-	O
lives	O
in	O
blood	O
.	O

Cationic	O
peptides	O
are	O
not	O
stable	O
in	O
the	O
serum	O
due	O
to	O
high	O
susceptibility	O
to	O
enzymatic	O
degradation	O
.	O

hBD3	B-GP
was	O
observed	O
to	O
be	O
completely	O
digested	O
in	O
contact	O
with	O
simulated	O
gastric	O
fluid	O
[	O
43	O
].	O

One	O
solution	O
to	O
the	O
limitations	O
is	O
gene	O
delivery	O
of	O
hBD3	B-GP
.	O

Another	O
way	O
is	O
to	O
develop	O
a	O
structurally	O
modified	O
peptide	O
of	O
hBD3	B-GP
with	O
certain	O
biological	O
activity	O
.	O

Notable	O
examples	O
include	O
a	O
C	O
-	O
terminus	O
peptide	O
and	O
a	O
linear	O
hBD3	B-GP
peptide	O
with	O
anti	O
-	O
inflammatory	O
and	O
antifungal	O
activities	O
[	O
44	O
–	O
46	O
].	O

This	O
may	O
provide	O
new	O
therapeutic	O
approaches	O
to	O
harness	O
the	O
pharmaceutical	O
potential	O
of	O
hBD3	B-GP
.	O

However	O
,	O
the	O
endothelial	O
cells	O
we	O
used	O
in	O
this	O
study	O
were	O
obtained	O
from	O
the	O
human	B-OG
umbilical	O
vein	O
,	O
not	O
aortas	O
,	O
which	O
are	O
the	O
main	O
location	O
forming	O
atherosclerotic	O
plaques	O
.	O

The	O
difference	O
in	O
physiology	O
and	O
shear	O
stress	O
between	O
veins	O
and	O
arteries	O
might	O
contribute	O
to	O
heterogeneity	O
between	O
ECs	O
in	O
veins	O
and	O
aortas	O
[	O
47	O
–	O
49	O
].	O

In	O
addition	O
,	O
some	O
differences	O
in	O
the	O
immune	O
response	O
to	O
proinflammatory	B-GP
cytokines	I-GP
,	O
such	O
as	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
might	O
exist	O
.	O

Further	O
confirmation	O
in	O
animal	O
models	O
should	O
be	O
performed	O
to	O
uncover	O
the	O
underlying	O
molecular	O
mechanisms	O
.	O

In	O
addition	O
,	O
cell	O
density	O
was	O
identified	O
to	O
have	O
an	O
impact	O
on	O
the	O
immune	O
response	O
of	O
HUVECs	O
[	O
50	O
].	O

5	O
.	O

Conclusion	O

In	O
summary	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
cell	O
activation	O
can	O
be	O
reversed	O
by	O
treatment	O
with	O
hBD3	B-GP
.	O

Furthermore	O
,	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
hBD3	B-GP
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
treated	O
HUVECs	O
seem	O
to	O
be	O
closely	O
related	O
to	O
downregulation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
and	O
MAPK	B-GP
pathway	O
.	O

Effects	O
of	O
hBD3	O
on	O
TNF	O
-	O
α	O
-	O
induced	O
cell	O
death	O
.	O

HUVECs	O
were	O
treated	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
and	O
various	O
concentrations	O
of	O
hBD3	O
for	O
24	O
h	O
.	O

The	O
cell	O
viability	O
of	O
HUVECs	O
was	O
determined	O
with	O
a	O
CCK8	O
assay	O
according	O
to	O
the	O
instructions	O
of	O
manufacturers	O
.	O

Data	O
are	O
presented	O
as	O
the	O
survival	O
rate	O
compared	O
to	O
the	O
control	O
group	O
,	O
which	O
is	O
defined	O
as	O
100	O
%.	O

Values	O
represent	O
the	O
means	O
±	O
SD	O
(	O
n	O
=	O
6	O
).	O
###	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
the	O
control	O
group	O
.	O
∗∗	O
p	O
<	O
0	O
.	O
01	O
,	O
∗∗∗	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
TNF	O
-	O
α	O
group	O
.	O

Effects	O
of	O
hBD3	O
on	O
IL	O
-	O
8	O
,	O
IL	O
-	O
6	O
,	O
MCP	O
-	O
1	O
,	O
and	O
MIF	O
production	O
in	O
TNF	O
-	O
α	O
-	O
stimulated	O
HUVECs	O
.	O

Cells	O
were	O
incubated	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
various	O
concentrations	O
of	O
hBD3	O
for	O
24	O
h	O
.	O

Then	O
,	O
the	O
culture	O
supernatants	O
were	O
collected	O
by	O
centrifugation	O
and	O
analyzed	O
by	O
ELISA	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Data	O
are	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
(	O
n	O
=	O
6	O
).	O
###	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
the	O
control	O
group	O
.	O
∗	O
p	O
<	O
0	O
.	O
05	O
,	O
∗∗	O
p	O
<	O
0	O
.	O
01	O
,	O
and	O
∗∗∗	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
TNF	O
-	O
α	O
group	O
.	O

The	O
effects	O
of	O
hBD3	O
on	O
the	O
expression	O
of	O
adhesion	O
molecules	O
in	O
TNF	O
-	O
α	O
-	O
activated	O
HUVECs	O
.	O

(	O
a	O
)	O
HUVECs	O
were	O
incubated	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
the	O
indicated	O
concentrations	O
of	O
hBD3	O
for	O
24	O
h	O
(	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
analysis	O
)	O
or	O
4	O
h	O
(	O
E	O
-	O
selectin	O
analysis	O
).	O

Whole	O
cell	O
lysates	O
were	O
extracted	O
and	O
analyzed	O
by	O
western	O
blot	O
using	O
antibodies	O
specific	O
to	O
VCAM	O
-	O
1	O
,	O
ICAM	O
-	O
1	O
,	O
and	O
E	O
-	O
selectin	O
.	O

(	O
b	O
)	O
Immunofluorescence	O
analysis	O
for	O
ICAM	O
-	O
1	O
expression	O
was	O
conducted	O
as	O
mentioned	O
above	O
,	O
and	O
images	O
were	O
obtained	O
using	O
a	O
fluorescence	O
microscope	O
(	O
original	O
magnification	O
:	O
400x	O
,	O
scale	O
bar	O
50	O
μm	O
).	O

Effects	O
of	O
hBD3	O
on	O
TNF	O
-	O
α	O
-	O
induced	O
adhesion	O
to	O
THP	O
-	O
1	O
cells	O
in	O
HUVECs	O
.	O

HUVECs	O
were	O
stimulated	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
and	O
the	O
indicated	O
concentrations	O
of	O
hBD3	O
for	O
24	O
h	O
.	O

After	O
stimulation	O
,	O
HUVECs	O
were	O
cocultured	O
with	O
calcein	O
-	O
AM	O
-	O
labeled	O
THP	O
-	O
1	O
cells	O
for	O
30	O
min	O
.	O

(	O
a	O
)	O
Images	O
were	O
captured	O
using	O
a	O
fluorescence	O
microscope	O
(	O
original	O
magnification	O
:	O
100x	O
).	O

(	O
b	O
)	O
Adherent	O
cells	O
were	O
measured	O
using	O
a	O
microplate	O
reader	O
at	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
490	O
nm	O
and	O
515	O
nm	O
,	O
respectively	O
.	O

The	O
results	O
were	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
3	O
.	O
###	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
the	O
control	O
group	O
.	O
∗∗	O
p	O
<	O
0	O
.	O
01	O
compared	O
with	O
TNF	O
-	O
α	O
group	O
.	O

Effects	O
of	O
hBD3	O
on	O
TNF	O
-	O
α	O
-	O
induced	O
NF	O
-	O
κB	O
and	O
MAPK	O
activation	O
in	O
HUVECs	O
.	O

(	O
a	O
)	O
HUVECs	O
were	O
incubated	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
the	O
indicated	O
concentrations	O
of	O
hBD3	O
for	O
30	O
min	O
.	O

Whole	O
cell	O
lysates	O
were	O
centrifuged	O
and	O
analyzed	O
with	O
western	O
blot	O
using	O
specific	O
antibodies	O
.	O

(	O
b	O
)	O
Immunofluorescence	O
analysis	O
for	O
NF	O
-	O
κB	O
p65	O
localization	O
was	O
conducted	O
as	O
mentioned	O
above	O
,	O
and	O
images	O
were	O
captured	O
using	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
system	O
(	O
Nikon	O
A1	O
,	O
Japan	O
)	O
(	O
original	O
magnification	O
:	O
400x	O
,	O
scale	O
bar	O
50	O
μm	O
).	O

(	O
c	O
)	O
HUVECs	O
were	O
incubated	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
the	O
indicated	O
concentrations	O
of	O
hBD3	O
for	O
30	O
min	O
and	O
45	O
min	O
.	O

Whole	O
cell	O
lysates	O
were	O
centrifuged	O
and	O
analyzed	O
with	O
western	O
blot	O
using	O
specific	O
antibodies	O
.	O

hBD3	O
inhibits	O
HUVEC	O
apoptosis	O
stimulated	O
by	O
TNF	O
-	O
α	O
.	O

After	O
incubation	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
and	O
different	O
concentrations	O
of	O
hBD3	O
for	O
6	O
h	O
,	O
the	O
protein	O
levels	O
of	O
cleaved	O
caspase	O
-	O
3	O
and	O
β	O
-	O
actin	O
in	O
HUVECs	O
were	O
detected	O
with	O
an	O
immunoblot	O
assay	O
.	O

Inhibitory	O
effects	O
of	O
hBD3	O
on	O
TNF	O
-	O
α	O
-	O
induced	O
ROS	O
formation	O
in	O
HUVECs	O
.	O

HUVECs	O
were	O
incubated	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
and	O
hBD3	O
(	O
15	O
μg	O
/	O
mL	O
)	O
for	O
2	O
h	O
.	O

Intracellular	O
ROS	O
accumulation	O
was	O
determined	O
by	O
observation	O
under	O
a	O
fluorescence	O
microscope	O
(	O
a	O
)	O
or	O
fluorescence	O
measurement	O
with	O
a	O
microplate	O
reader	O
(	O
b	O
)	O
after	O
incubation	O
with	O
the	O
ROS	O
detector	O
DCFH	O
-	O
DA	O
for	O
30	O
min	O
(	O
original	O
magnification	O
:	O
400x	O
).	O

Values	O
represent	O
the	O
mean	O
±	O
SD	O
.	O
###	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
the	O
control	O
group	O
;	O
∗∗∗	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
TNF	O
-	O
α	O
alone	O
.	O

Effects	O
of	O
hBD3	O
on	O
TNF	O
-	O
α	O
-	O
induced	O
F	O
-	O
actin	O
rearrangement	O
.	O

HUVECs	O
were	O
incubated	O
with	O
TNF	O
-	O
α	O
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
hBD3	O
(	O
15	O
μg	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O

After	O
that	O
,	O
cells	O
were	O
washed	O
with	O
PBS	O
.	O

F	O
-	O
actin	O
was	O
stained	O
with	O
DyLight	O
488	O
-	O
phalloidin	O
for	O
15	O
min	O
in	O
the	O
dark	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Images	O
were	O
obtained	O
using	O
a	O
confocal	O
microscope	O
(	O
Olympus	O
FV10i	O
)	O
(	O
original	O
magnification	O
:	O
600x	O
,	O
scale	O
bar	O
50	O
μm	O
).	O

